Canada markets closed

Standard BioTools Inc. (LAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5700+0.0700 (+2.80%)
At close: 04:00PM EDT
2.5800 +0.01 (+0.39%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.5000
Open2.5000
Bid2.5300 x 700
Ask2.5800 x 800
Day's Range2.4850 - 2.5900
52 Week Range1.5700 - 3.1600
Volume2,933,993
Avg. Volume2,505,266
Market Cap973.673M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.0000
Earnings DateAug 06, 2024 - Aug 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
  • Insider Monkey

    Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript

    Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript May 11, 2024 Standard BioTools Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Standard BioTools Inc. First Quarter 2024 Earnings Conference Call. All participants […]

  • GlobeNewswire

    Standard BioTools Reports First Quarter 2024 Financial Results

    Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, res

  • GlobeNewswire

    Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

    Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while suppo